Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice

Figure 5

Adjuvant Aviscumine treatment of glioma bearing mice. (a) Scheme of the treatment of mice bearing orthotopic LNT-229 tumors. (b) Kaplan Mayer survival curves. Mice were intratumorally sham-injected with PBS or with Aviscumine (Avi, 0.72 ng ML in total, dotted line) at day 10. Focal tumor irradiation (3 Gy) was performed at day 11 followed by weekly intraperitoneal TMZ injections (1.5 mg/kg) for three weeks. Adjuvant Aviscumine treatment resulted in a trend for prolonged survival compared to the radio-chemotherapeutic treatment group and in a significant prolonged survival compared to the control group. (c) Median survival (n=6-8 animals, P-values, Log-rank test).